Volume 29, issue 6, June 2022

140 articles in this issue

1. Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps

2. Repeat CRS/HIPEC: It Comes Down to Tumor Biology and Ability to Achieve a Complete CRS

3. Deciphering the Etiology of Weight Loss Following Pancreatectomy

4. First Differentiate and Then Operate (Or Not)

5. Editorial Comment to “High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study”

6. Weighing in on Ghrelin and the Preservation of Muscle After Esophagectomy

7. Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM)

8. Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP)

9. Payer-Negotiated Prices for Breast Cancer Treatment at NCI-Designated Cancer Treatment Centers

10. A Framework for Reporting Cohort Derivation in Studies Using the National Cancer Database

11. Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases

12. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix

13. ASO Author Reflections: If at First You Don’t Succeed, Try, Try Again: Iterative CRS/HIPEC for Recurrent Mucinous Appendix Cancer

14. ASO Visual Abstract: Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix

15. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

16. ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

17. ASO Visual Abstract: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

18. Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms

19. ASO Author Reflections: When is the Best Time to Perform Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for a Recurrent Low-Grade Appendiceal Mucinous Neoplasm?

20. ASO Visual Abstract: Timing of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Recurrent Low-Grade Appendiceal Mucinous Neoplasms

21. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience

22. ASO Author Reflections: Thirty Years of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Wake Forest University

23. ASO Visual Abstract: Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis—A 30-year Institutional Experience

24. Weight Tracking as a Novel Prognostic Marker After Pancreatectomy

25. ASO Author Reflection: Post-pancreatectomy Weight Trends Predict Recurrence and Survival

26. ASO Visual Abstract: Weight Tracking as a Novel Prognostic Marker After Pancreatectomy

27. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough?

28. ASO Author Reflections: An Underappreciated Metric: Systemic Chemotherapy Dose Density in Pancreatic Cancer

29. ASO Visual Abstract: Systemic Therapy for Resected Pancreatic Adenocarcinoma—How Much Is Enough?

30. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol

31. ASO Author Reflection: Location of Nodal Metastases in Pancreatoduodenectomy for Cancer: Which Station Matters?

32. ASO Visual Abstract: Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective Lymphadenectomy Protocol

33. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC)

34. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System

35. ASO Visual Abstract: Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma

36. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with Videos)

37. Comment on “Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy”

38. More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis

39. Reply to: Letter to the Editor: More is More? Total Pancreatectomy for Periampullary Cancer as an Alternative in Patients with High-Risk Pancreatic Anastomosis: A Propensity Score-Matched Analysis, by Marchegiani, Giovanni et al.

40. Correction to: Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study

41. Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis

42. ASO Author Reflections: Reconsidering Resection for Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma

43. ASO Visual Abstract: Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma—An NCDB Analysis

44. Clinical Predictors of Pseudohypoxia-Type Pheochromocytomas

45. ASO Author Reflections: Clinical Predictors of Pseudohypoxia Cluster Type Pheochromocytomas

46. ASO Visual Abstract: Clinical Predictors of Pseudohypoxia-Type Pheochromocytoma

47. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study

48. ASO Visual Abstract: High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study

49. Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival

50. ASO Visual Abstract: Hepatectomy with Perioperative Chemotherapy for Multiple Colorectal Liver Metastases is the Available Option for Prolonged Survival

51. Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers

52. ASO Author Reflections: Broaden the Targeted Population of Synthetic Lethality for Taiwanese Breast Cancer

53. Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases

54. Perioperative Ghrelin Administration Attenuates Postoperative Skeletal Muscle Loss in Patients Undergoing Esophagectomy for Esophageal Cancer: Secondary Analysis of a Randomized Controlled Trial

55. ASO Author Reflections: Can Perioperative Ghrelin Administration Inhibit Postoperative Muscle Mass Loss in Esophageal Cancer Patients?

56. ASO Visual Abstract: Perioperative Ghrelin Administration Attenuates Postoperative Skeletal Muscle Loss in Patients Undergoing Esophagectomy for Esophageal Cancer—Secondary Analysis of a Randomized, Controlled Trial

57. Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone for Esophageal Squamous Cell Carcinoma

58. ASO Visual Abstract: Survival Comparison Among Neoadjuvant Chemoradiotherapy Followed by Esophagectomy, Definitive Chemoradiotherapy, and Esophagectomy Alone in Esophageal Squamous Cell Carcinoma

59. Influence of Race, Insurance, Rurality, and Socioeconomic Status on Equity of Lung and Colorectal Cancer Care

60. ASO Author Reflections: Intersectionality of Social Determinants of Health in Lung and Colorectal Cancer Diagnosis and Treatment

61. ASO Visual Abstract: Influence of Race, Insurance, Rurality, and Socioeconomic Status on Equity of Lung and Colorectal Cancer Care

62. Neoadjuvant Therapy Versus Upfront Surgery for Patients With Clinical Stage 2 or 3 Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

63. ASO Author Reflections: Opting for a Cost-Effective Treatment Allocation in Patients with Esophageal Cancer

64. ASO Visual Abstract: Neoadjuvant Therapy Versus Upfront Surgery for Patients with Clinical Stage II and III Esophageal Squamous Cell Carcinoma—A Cost-Effectiveness Analysis

65. The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma

66. ASO Author Reflections: Improvement of Esophageal Cancer Staging by Implementing Mandard Tumor Regression Score

67. ASO Visual Abstract: The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma

68. Actual Sarcopenia Reflects Poor Prognosis in Patients with Esophageal Cancer

69. ASO Author Reflections: Actual Sarcopenia in Esophageal Cancer Patients

70. ASO Visual Abstract: Actual Sarcopenia Reflects Poor Prognosis in Patients with Esophageal Cancer

71. Survival Benefit from Surgical Resection in Lung Cancer Patients with Brain Metastases: a Single-Center, Propensity-Matched Analysis Cohort Study

72. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

73. Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis

74. ASO Visual Abstract: Outcomes Following Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-Analysis

75. Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)

76. ASO Author Reflections: 1400 IORT Cases—A Christmas Miracle

77. ASO Visual Abstract: Recurrence and Survival Rates for 1400 Early Breast Tumors Treated with Intraoperative Radiation Therapy (IORT)

78. Mastectomy or Margin Re-excision? A Nomogram for Close/Positive Margins After Lumpectomy for DCIS

79. ASO Visual Abstract: Mastectomy or Margin Reexcision? A Nomogram for Close/Positive Margins after Lumpectomy for DCIS

80. Review of Cancer-Specific Quality Measures Promoting the Avoidance of Low-Value Care

81. ASO Visual Abstract: Review of Cancer-Specific Quality Measures Promoting the Avoidance of Low-Value Care

82. How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study

83. ASO Author Reflections: Is It Necessary to Routinely Clip and Localize the Biopsy-Proven Malignant Lymph Node?

84. ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study

85. Initial Experience Using Magseed for Breast Lesion Localization Compared With Wire-Guided Localization: Analysis of Volume and Margin Clearance Rates

86. ASO Visual Abstract: Initial Experience Using Magseed for Breast Lesion Localization Compared to Wire-Guided Localization—Analysis of Volume and Margin Clearance Rates

87. Impact of Quilting Sutures on Surgical Outcomes After Mastectomy: A Systematic Review and Meta-Analysis

88. ASO Author Reflections: Role of Quilting Sutures in Mastectomies

89. ASO Visual Abstract: Impact of Quilting Sutures on Surgical Outcomes After Mastectomy: A Systematic Review and Meta-Analysis

90. Association of Preoperative Sarcopenia with Adverse Outcomes of Breast Reconstruction Using Deep Inferior Epigastric Artery Perforator Flap

91. ASO Visual Abstract: Association of Preoperative Sarcopenia with Adverse Outcomes of Breast Reconstruction Using Deep Inferior Epigastric Artery Perforator Flap

92. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer

93. ASO Visual Abstract: Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer

94. Clinical Outcomes Using Magnetic Seeds as a Non-wire, Non-radioactive Alternative for Localization of Non-palpable Breast Lesions

95. Satisfaction of Patients Who Received Breast-Conserving Surgery Using the Suture Scaffold Technique: A Single-Institution, Cross-Sectional Study

96. ASO Author Reflections: Patients’ Satisfaction After Breast Conserving Surgery Using the Suture Scaffold Technique

97. ASO Visual Abstract: Satisfaction of Patients Who Received Breast-Conserving Surgery Using the Suture Scaffold Technique: A Single-Institution, Cross-Sectional Study

98. Additional Workups Recommended During Preoperative Breast MRI: Methods to Gain Efficiency and Limit Confusion

99. ASO Author Reflections: Optimizing Additional Workups from Preoperative Breast MRI

100. ASO Visual Abstract: Additional Work-Ups Recommended During Preoperative Breast MRI, Methods to Gain Efficiency and Limit Confusion

101. ASO Author Reflections: The Evolving Multidisciplinary Management of the Axilla in Mastectomy Patients

102. ASO Author Reflections: Preventing Nipple Loss by Surgical Delay in Nipple-Sparing Mastectomy

103. ASO Author Reflections: Volumetric Specimen Imaging for Margin Assessment in Breast Cancer

104. ASO Author Reflections: The Patient Perspective of Telemedicine in Breast Cancer Care

105. ASO Visual Abstract: A 5-Year Breast Surgeon Experience in LYMPHA at Time of ALND for Treatment of Clinical T1–4N1–3M0 Breast Cancer

106. ASO Visual Abstract: Improving the Breast Surgeon’s Ergonomic Workload for Nipple-Sparing Mastectomies Using Exercise and an Operating Room Positioning Protocol

107. ASO Visual Abstract: Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer

108. ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy

109. Correction to: Development and Evaluation of a Machine Learning Prediction Model for Flap Failure in Microvascular Breast Reconstruction

110. Association of Albumin-Bilirubin Grade and Myosteatosis with its Prognostic Significance for Patients with Colorectal Cancer

111. ASO Author Reflections: Albumin–Bilirubin Grade and Myosteatosis as Potential Cancer Cachexia-Related Indicators in Patients with Colorectal Cancer

112. ASO Visual Abstract: Association Between Albumin–Bilirubin Grade and Myosteatosis and Its Prognostic Significance for Patients with Colorectal Cancer

113. Prosthetic Reconstruction of the Cavo-Hepatic Venous Confluence for a Colorectal Cancer Liver Recurrence

114. ASO Author Reflections: Resection of Colorectal Cancer Liver Metastasis with Vascular Invasion

115. Correction to: Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial

116. Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer

117. ASO Author Reflections: The Role of Robotic Gastrectomy for Gastric Cancer

118. ASO Visual Abstract: Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer

119. Effects of Proximal Gastrectomy and Various Clinical Factors on Postoperative Quality of Life for Upper-third Gastric Cancer Assessed using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45): A PGSAS NEXT Study

120. ASO Visual Abstract: Effects of Proximal Gastrectomy and Various Clinical Factors on Postoperative Quality of Life for Upper-Third Gastric Cancer Assessed Using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45): A PGSAS NEXT Study

121. Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population

122. ASO Visual Abstract: Clinical Relevance of the Tumor Location-Modified Laurén Classification System of Gastric Cancer in a Western Population

123. Less Severe Intra-Abdominal Infections in Robotic Surgery for Gastric Cancer Compared with Conventional Laparoscopic Surgery: A Propensity Score-matched Analysis

124. ASO Visual Abstract: Less Severe Intra-abdominal Infections in Robotic Surgery for Gastric Cancer Compared with Conventional Laparoscopic Surgery: A Propensity Score-Matched Analysis

125. Transthoracic Single-Port Assisted Laparoscopic Five-Step Maneuver Lower Mediastinal Lymphadenectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction

126. Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy

127. ASO Visual Abstract: Prediction of Therapeutic Effect of Treatment on Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study Comparing Bevacizumab-Containing Chemotherapy and Standard Chemotherapy

128. Real-Time Wireless Tumor Tracking in Navigated Liver Resections: An Ex Vivo Feasibility Study

129. ASO Visual Abstract: Real-Time Wireless Tumor Tracking in Navigated Liver Resections—an Ex Vivo Feasibility Study

130. Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma

131. ASO Visual Abstract: A Glycolysis-Related Gene Signature Can Predict Survival and Immune Status of Hepatocellular Carcinoma

132. Triple Intercostal Transthoracic Ports in Laparoscopic Hepatectomy for a Tumor in a Cranially Protruded Liver (with Video)

133. ASO Author Reflections: Feasibility of Triple Intercostal Trans-thoracic Ports in Laparoscopic Hepatectomy

134. Correction to: Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis

135. Frailty in Very Elderly Patients is Not Associated with Adverse Surgical or Oncological Outcomes in Extremity Surgery for Soft Tissue Sarcoma

136. ASO Visual Abstract: Frailty in Very Elderly Patients is not Associated with Adverse Surgical or Oncological Outcomes in Extremity Surgery for Soft Tissue Sarcoma

137. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery

138. ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery

139. ASO Visual Abstract: Preoperative Denosumab Therapy against Giant Cell Tumor of Bone Is Associated with an Increased Risk of Local Recurrence after Curettage Surgery

140. Correction to: Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma